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Abstract: Experimental models of neuroendocrine tumor disease are scarce, with only a few
existing neuroendocrine tumor cell lines of pancreatic origin (panNET). Their molecular
characterization has so far focused on the neuroendocrine phenotype and cancer-related mutations,
while a transcription-based assessment of their developmental origin and malignant potential
is lacking. In this study, we performed immunoblotting and qPCR analysis of neuroendocrine,
epithelial, developmental endocrine-related genes as well as next-generation sequencing (NGS)
analysis of microRNAs (miRs) on three panNET cell lines, BON-1, QGP-1, and NT-3. All three
lines displayed a neuroendocrine and epithelial phenotype; however, while insulinoma-derived
NT-3 cells preferentially expressed markers of mature functional pancreatic β-cells (i.e., INS, MAFA),
both BON-1 and QGP-1 displayed high expression of genes associated with immature or non-functional
β/δ-cells genes (i.e., NEUROG3), or pancreatic endocrine progenitors (i.e., FOXA2). NGS-based
identification of miRs in BON-1 and QGP-1 cells revealed the presence of all six members of
the miR-17–92 cluster, which have been implicated in β-cell function and differentiation, but also
have roles in cancer being both oncogenic or tumor suppressive. Notably, both BON-1 and QGP-1
cells expressed several miRs known to be negatively associated with epithelial–mesenchymal
transition, invasion or metastasis. Moreover, both cell lines failed to exhibit migratory activity in vitro.
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Taken together, NT-3 cells resemble mature functional β-cells, while both BON-1 and QGP-1 are
more similar to immature/non-functional pancreatic β/δ-cells or pancreatic endocrine progenitors.
Based on the recent identification of three transcriptional subtypes in panNETs, NT-3 cells resemble
the “islet/insulinoma tumors” (IT) subtype, while BON-1 and QGP-1 cells were tentatively classified
as “metastasis-like/primary” (MLP). Our results provide a comprehensive characterization of three
panNET cell lines and demonstrate their relevance as neuroendocrine tumor models.
Keywords: pancreatic neuroendocrine tumor; BON-1; QGP-1; NT-3; β-cell; EMT; microRNA
1. Introduction
Preclinical models of neuroendocrine tumors (NET) currently encompass only a limited number
of human NET cell lines and mouse models. The most commonly used human neuroendocrine
neoplastic cell lines of gastroenteropancreatic (GEP)-NET origin encompass the pancreatic NET
(panNET) cell lines BON-1 (BON) [1], QGP-1 (QGP) [2,3], and CM [4] as well as the small intestinal
NET (siNET) cell lines GOT-1, KRJ-I, P-STS, H-STS, and L-STS. However, GEP-NET cell lines have only
partially been characterized and, hence, several issues still remain open: i) Their authenticity with
regard to their neuroendocrine origin and phenotype, ii) their genomic and mutational characteristics,
and iii) the identity of their normal counterparts from which they were originally derived. Recently, in
the course of analyzing a panel of siNET and panNET cell lines by exome sequencing and genome-wide
copy number, it was revealed that the KRJ-I, H-STS, and L-STS lines did not exhibit a neuroendocrine
phenotype and are in fact lymphoblastoid cells [5]. For other cell lines, their mutation patterns,
and proliferation rates seem distinct from well-differentiated NETs in patients [5–7] and thus might not
adequately reflect the tumor biology of well-differentiated NETs. Specifically, for panNET, studies in
BON and QGP cells have raised questions regarding their relevance as models due to the absence
of mutations in MEN1 [5–7] or low SSTR expression [8]. Together, this emphasizes the need for
careful reevaluation and further characterization of the existing cell lines. One aim of the present
study was; therefore, to confirm the authenticity of the BON and QGP cell lines with respect to their
neuroendocrine and epithelial phenotype, developmental origin, and propensity for cell motility
in vitro.
Although BON and QGP cells have been compared for the expression of some classical
neuroendocrine markers to a recently established patient-derived panNET cell line (NT-3, [9]) and to
panNET tissues [8], such a comparison has not yet been performed for other cellular features such as
epithelial/mesenchymal differentiation, expression of genes governing immature and mature β-cell
function and differentiation from pancreatic (endocrine) progenitors, or microRNA (miR) signatures.
Earlier, we have performed miR profiling in GEP-NET and panNET tissues [10,11]; however, tumor
tissues are heterogeneous with respect to cellular composition and, hence, their analysis does not allow
for the identification of miRs expressed specifically by the tumor cell fraction.
Recently, a cross-species analysis has revealed the existence of previously unrecognized subtypes
of panNET in both mice and humans, and could assign different mutations and phenotypic, clinical,
and pathologic properties to these tumor subtypes underlying the heterogeneous biology of this
disease. Specifically, dual mRNA and miR transcriptome profiling analysis has identified three
distinct molecular subtypes and associated biomarkers in human panNET, termed “islet/insulinoma
tumors” (IT), “metastasis-like/primary” (MLP), and “intermediate” [12]. PanNETs of the IT subtype
consist primarily of less-aggressive, non-metastatic insulinomas that expressed genes associated
with insulinomas and differentiated/mature β-cells. In contrast, tumors of the MLP subtype are
invasive/metastatic and their signatures are enriched for genes associated with immature non-functional
β-cells, and eventually EMT, fibroblasts/stroma, and stem cells, implicating a progenitor origin.
The intermediate subtype includes mostly nonfunctional panNETs, shares many genes with the IT
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subtype, and is moderately associated with metastasis. An association of the newly-defined
transcriptional subtypes with the WHO classification of NET grades showed that G1 and G2 human
panNETs are heterogeneous, variably associating with all three transcriptome subtypes, whereas
high-grade NET G3 tumors are exclusively associated with the MLP subtype [12].
Based on results from other studies we postulate that BON and QGP cells possess, at least partially,
a neuroendocrine and well-differentiated epithelial phenotype associated with a low invasive potential.
However, since both lines classify as tumor cells they might have undergone a dedifferentiation process
or, alternatively, have turned malignant already at an early developmental stage. In this case these cells
should resemble immature islet cells or pancreatic precursors. To analyze this in more detail, we have
carried out a comprehensive phenotypic characterization of the BON and QGP cell lines with respect to
their differentiation and developmental states by protein, mRNA and miR expression analyses as well
as to their invasive potential by assessing the cells’ migratory ability in vitro. In addition, attempted
an allocation of both cell lines to one of the above mentioned molecular subtypes of panNETs.
2. Results
2.1. Expression of Markers of Neuroendocrine Differentiation
Initially, we evaluated the extent of neuroendocrine differentiation of BON and QGP cells by
measuring the expression of a panel of neuroendocrine markers using quantitative real-time RT-PCR
(qPCR) and immunoblot analysis. A primary panNET cell line, NT-3, recently characterized by us [9],
was used as control. We found, in Western blot analysis, strong signals for Synaptophysin (SYP) in NT-3
cells and weaker ones in BON and QGP cells (Figure 1A, upper blot). The expression of Chromogranin
A (CgA, encoded by CHGA) was quite similar at both the mRNA and protein level, except that no
specific signals were detectable for QGP in the immunoblots (Figure 1B).
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Figure 1. Expression of markers of neuroendocrine differentiation in BON and QGP cells, and NT-3 
cells as control. (A) Immunoblot analysis of synaptophysin (SYP), and heat shock protein 90 
(HSP90) as a loading control, in NT-3, BON, and QGP cells. The graph underneath the blot depicts 
the relative (Rel.) protein abundance calculated from the densitometric readings of band intensities 
(mean ± SD, n = 3) from three independent experiments, relative to NT-3 set arbitrarily at 1.0. The 
numbers to the left indicate band sizes of the molecular weight marker (M). (B) Quantitative real-
Figure 1. Expression of markers of neuroendocrine differentiation in BON and QGP cells, and NT-3
cells as control. (A) Immunoblot analysis of synaptophysin (SYP), and heat shock protein 90 (HSP90)
as a loading control, in NT-3, BON, and QGP cells. The graph underneath the blot depicts the relative
(Rel.) protein abundance calculated from the densitometric readings of band intensities (mean ± SD,
n = 3) from three independent experiments, relative to NT-3 set arbitrarily at 1.0. The numbers to
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the left indicate band sizes of the molecular weight marker (M). (B) Quantitative real-time RT-PCR
(qPCR, left-hand side) and qualitative immunoblot analysis (right-hand side) of chromogranin A (CgA).
The qPCR data represent the mean ± SD from three to four cell preparations normalized to TATA
box-binding protein (TBP). Signals for BON cells on immunoblots only became visible after an extended
exposure (Exp.) time. The longer exposure time is also evident from the stronger bands of the molecular
weight marker. The thin lines indicate removal of irrelevant lanes. (C) Immunoblot analysis of
somatostatin receptor 2 (SSTR2) in NT-3, BON, and QGP cells. Results from densitometry-based
quantification of the specific protein bands are given below the blots. (D) QPCR analysis of the indicated
genes. Data were derived from three to four cell preparations. The asterisks (∗) indicate significance
(p < 0.05, Wilcoxon test) relative to NT-3 cells. Human WI-38 fibroblasts were used as a negative control
in some qPCR assays; n.d., not detectable.
In BON, QGP, and NT-3 cells we also evaluated expression of somatostatin receptor 2 (SSTR2)
by both qPCR and immunoblotting. At the mRNA level, SSTR2 expression in BON was 2% and in
QGP 15% of the levels in NT-3 (Figure 1C), whereas signals for SSTR2 in the immunoblots were
comparatively weak in NT-3 cells and hardly detectable in BON and QGP cells (Figure 1C). The pattern
of SSTR5 mRNA expression was similar to that of SSTR2 with levels of BON and QGP being 6% and 32%,
respectively, that of NT-3 (Figure 1D). Additional markers of neuroendocrine differentiation included
Neural cell adhesion molecule 1 (NCAM1, encoded by NCAM1) which shows equal expression in
QGP and NT-3 whereas that in BON cells was ~30-fold lower (Figure 1D). The transcript levels of
Neurofilament light polypeptide (NFL, also termed Neurofilament 68, NF68, encoded by NEFL),
a member of the intermediate filament family, were 5.7-fold lower in BON and 26,000-fold lower in
QGP when compared to NT-3 cells (Figure 1D). Finally, expression of Microtubule-associated protein 2
(MAP2, encoded by MAP2) was 5-fold higher in QGP but 500-fold lower in BON than in NT-3 cells
(Figure 1D). These results confirm the neuroendocrine phenotype of BON and QGP cells albeit their
marker expression was generally lower than in NT-3 cells.
2.2. Expression of Markers of Epithelial/Mesenchymal Differentiation
The panNETs are likely derived from pancreatic ducts [13] and; therefore, should have an epithelial
phenotype. To confirm this, we assessed expression of the epithelial marker E-cadherin in BON
and QGP cells by immunoblotting. BON, QGP, and NT-3 cells were all strongly positive for E-cadherin
and protein levels were higher than in the two CDH1low PDAC-derived cell lines Panc1 and MiaPaCa2
(Figure 2A). To independently confirm the epithelial phenotype, we probed the same blot with
an antibody to the mesenchymal marker Vimentin, which should in this case result in low or absent
signals. To this end, Vimentin protein levels were low in BON and NT-3 and absent from QGP
cells (Figure 2B). This expression profile of E-cadherin/Vimentin in BON and QGP cells is indicative
of a well-differentiated epithelial phenotype and contrasts with the quasimesenchymal phenotype
(CDH1low/VIMhigh) of the Panc1 and MiaPaCa2 lines [14].
2.3. Expression of Genes of Islet Cell Hormones and Mature β-Cell Differentiation
As mentioned above, BON and QGP malignant conversion might have occurred at an early
developmental stage, in which case these cells should resemble immature rather than functional islet
cells, and eventually share some traits in common with pancreatic precursors. To verify or dismiss
such a scenario, we evaluated in BON, QGP, and NT-3 cells expression of Insulin, Glucagon, and SST
(encoded by INS1, GCG, and SST, respectively) by qPCR analysis. Consistent with its derivation from
an insulinoma, INS1 was found to be highly expressed and secreted by NT-3 cells [9]. Here, INS
mRNA was present in all three cell lines with expression in NT-3 being ~5-fold greater than in QGP
and ~100-fold greater than in BON cells (Figure 3). Likewise, GCG mRNA was 250–500-fold more
abundant in NT-3 vs. BON and QGP (Figure 3). Interestingly, we detected extremely high mRNA
levels for SST in QGP cells (~100-fold higher than in NT-3 and ~1000-fold higher than in BON cells,
Figure 3).
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Figure 2. Expression of epithelial and mesenchymal markers in BON, QGP and NT-3 cells. (A) Immunoblot
analysis of the epithelial marker E-cadherin. Capan2 or Panc1 and MiaPaCa2 cells were used as positive or
negative control, respectively. (B) Immunoblot analysis of the mesenchymal marker Vimentin. Capan2 or
Panc1 and MiaPaCa2 cells were used as negative or positive control, respectively. The graphs below the blots
indicate densitometry-based quantification of band intensities (mean ± SD, n = 3) from three independent
experiments (for NT-3 cells only the most representative one is shown). Data are plotted relative to NT-3 cells
set arbitrarily at 1.0. The values for Panc1 and MiaPaCa2 were not plotted (np) as they do not fit the scale.
The asterisk (∗) indicates a significant difference; ns, not significant.
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Figure 3. Quantitative real-time RT-PCR-based expression analysis of the indicated genes for islet hormones
(INS1, GCG, SST) and marker genes of mature β-cell differentiation or function (MAFA, PDX1, ACVR1C) in
BON, QGP, and NT-3 cells. Data represent the mean ± SD from three to four preparations. The asterisks (∗)
indicate significant differences relative to NT-3 cells (p < 0.05, Wilcoxon test).
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Next, we measured in BON, QGP, and NT-3 cells expression of MAFA, PDX1, and ACVR1C,
which are all mature β-cell-specific factors. MAFA, a marker gene of mature functional β-cells and key
regulator of glucose-stimulated insulin secretion, was expressed at a much higher level in NT-3
than in BON (~200-fold less) and QGP (~10-fold less) cells (Figure 3). PDX1 (also termed Insulin
promoter factor 1, IPF1) is a transcription factor (TF) that specifies the development of mono-hormonal
insulin-secreting cells and poly-hormonal pancreatic β-cells. The PDX1 gene is upregulated at later
stages of β-cell development, is restricted to β-cells in adult pancreas, and controls the expression
of MAFA and INS1. Its mRNA expression in NT-3 was ~10-fold higher than in BON and ~50-fold
higher than in QGP cells (Figure 3). The mRNA for activin receptor-like kinase 7 (ALK7, encoded by
ACVR1C), a receptor regulating insulin secretion and β-cell function in response to Nodal or Activin B
binding [15], was most abundant in NT-3 cells, being ~5-fold higher than in BON and ~10-fold higher
than in QGP cells (Figure 3). Taken together, when compared to NT-3 cells, BON and QGP cells are
characterized by much lower expression of markers of β-cell function and differentiation.
2.4. Expression of Genes of Immature β-Cells and Lineage-Specific Pancreatic Progenitors
Having shown that BON and QGP cells are largely deficient in mature β-cell-specific gene
expression, we pursued the idea that they resemble immature and non-functional pancreatic β-cells,
or endocrine progenitors. To test this possibility, we transcriptionally profiled BON and QGP cells
using a battery of genes involved in pancreatic, pancreatic endocrine, and islet cell differentiation.
PAX4 which is crucial for β- and δ-cell development, β/δ-cell lineage bifurcation, and conversion
of α- or δ-cells into functional β-like cells [16] is restricted at later stages to β-cells. We found that
the transcript levels for PAX4 are 10–20-fold more abundant in NT-3 cells than in the two permanent
cell lines (Figure 4A). Similarly, the related PAX6, which is expressed in all endocrine cells and increases
the number of islet cells, was ~10-fold higher in NT-3 than in QGP and ~1500-fold higher than in BON
cells (Figure 4A).Cancer  2020, 12, x FOR PEER REVIEW 7 of 18 
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BON and 50 miRs in QGP cells, of which 15 and 12 miRs, respectively, were novel and previously 
Figure 4. Quantitative real-time RT-PCR-based expression analysis of genes from immature β-cells
and pancreatic (endocrine) progenitors in BON, QGP, and NT-3 cells. The indicated genes were
grouped according to structural or functional similarities. (A) PAX4 and PAX6, (B) NEUROD1
and NEUROG3, (C) ISL1 and CDX2, (D) GATA4 and GATA6, (E) NKX2.2 and NKX6.1, (F) FOXA2
and PTF1A. Data represent the mean ± SD from three to four preparations. The asterisks (∗) indicate
significant differences relative to NT-3 cells (p < 0.05, Wilcoxon test), nd, not determined.
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NEUROD1 is a developmentally regulated gene that continues to be expressed in mature β-cells
and is essential for their maturation by assembling the insulin exocytotic machinery and driving
INS expression, and by downregulating genes that impair insulin secretion in β-cells. Interestingly,
NEUROD1 mRNA is 5-fold more abundant in BON than in NT-3 cells (Figure 4B). Likewise, expression
of Neurogenin3 (NGN3, encoded by NEUROG3) was ~4-fold higher in QGP compared to NT-3 cells
(Figure 4B). NGN3, a marker for pancreatic endocrine progenitors and activator of TFs responsible for
differentiation of the endocrine precursors into mono-hormonal islet cells, disappears during the final
stage of β-cell differentiation [17].
ISL1, a TF binding to INS enhancer sequences, is 43-fold lower in BON compared to NT-3
cells (Figure 4C). In contrast, CDX2 which by synergistic interactions with PAX6 can activate gene
transcription of GCG (Figure 4C), GATA4, a TF expressed during early pancreatic budding, and GATA6
were either equally expressed in BON, QGP and NT-3 (CDX2, GATA4) or were even higher in BON
and QGP compared to NT-3 cells (GATA6). The mRNA abundance of NKX2.2, a TF important for
development of α-, β-, and δ-cells and for maintenance of β-cell identity, is 3-fold lower in BON
and 30-fold lower in QGP than in NT-3 cells (Figure 4E), while NKX6.1, which is crucial for islet
endocrine cell development and insulin secretion in β-cells, is 3-fold lower in QGP and 1500-fold lower
in BON cells (Figure 4E).
HNF3β/FOXA2 is a TF expressed in foregut endoderm which differentiates into pancreatic buds.
Its expression continues in all pancreatic cell types and during pancreatic development and peaks in
pancreatic islets where it is important for the development and functionality of β-cells. Interestingly,
FOXA2 transcript levels are 3–4-fold higher in both BON and QGP compared to NT-3 cells (Figure 4F).
PTF1A, a gene that plays a role in determining whether cells allocated to the pancreatic buds continue
towards pancreatic organogenesis or revert to duodenal fates, has its strongest expression in QGP
cells, being 70-fold higher and in BON 6.5-fold higher than in NT-3 cells (Figure 4F). The data from
the developmental gene expression survey clearly show that BON and QGP cells have higher expression
of genes involved in pancreatic and early but not late endocrine differentiation of the pancreas.
2.5. Identification of MiRs Expressed in BON and QGP Cells
MiRs are involved in various aspects of cellular function, normal pancreas development, islet
differentiation, or pancreatic tumorigenesis [18], and represent potential prognostic markers in NET [19].
For identification of miRs we subjected total RNA samples of untreated BON, QGP, and NT-3 cells
to next-generation sequencing (NGS) analysis. We were able to identify a total of 43 miRs in BON
and 50 miRs in QGP cells, of which 15 and 12 miRs, respectively, were novel and previously unknown
(Table S1). Several of the known miRs expressed in BON and QGP cells (Let7F1, 7–3, 17, 19B1, 20A,
33A, 182, 221, 664b, 1225, 1248, 3609, 3653) as well as some novel miRs were moderately or even highly
abundant with relative expression scores (RESs) ranging from 0 to 12,533. Some miRs were selectively
expressed only in BON (15a, 15b, 126, 129–1, 431, 503, 3618, 3913–2, 6516, 6820, 6895) or QGP (7–1,
17, 18a, 19a, 21, 29b2, 92a1, 98, 146a, 196A2, 483, 671, 3131, 3691, 6789, LET7B, LET7F1) cells, or were
shared by both lines (7–3, 17, 19b1, 20a, 33a, 141, 182, 221, 664B, 1225, 1248, 3609, 3653) (Table S1).
We hypothesized that the miR signatures of BON, QGP, and NT-3 cells should exhibit a partial
overlap in miRs involved in differentiation and development. In contrast, miRs regulating mature β-cell
function should be enriched in NT-3 cells, while those associated with malignancy or response to drug
treatment should predominate in BON and QGP cells. To this end, all three cell lines, to a various extent,
express the six members of the miR-17–92 cluster (17, 18a, 19a, 19b-1, 20a, 92a), a highly-conserved
gene cluster with various roles in β-cell function and differentiation [20–24]. Yet other miRs involved
in β-cell/islet cell development and insulin secretion (7–3, 15a, 33a, 182, and 375 [25–30]) are more
prominent in NT-3 than in BON and QGP cells. For instance, miR-375, which was only detected in
NT-3 but not in BON or QGP cells, is one of the most abundant miRs in the islets and has multiple
functions, such as control of β-cell identity and β-cell mass as well as regulation of insulin secretion [31].
In fact, the malignant nature of the BON and QGP cells was evident from the expression of miRs
Cancers 2020, 12, 691 8 of 18
for which oncogenic or anti-oncogenic effects have been reported (i.e., the miR-17–92 cluster that
also exhibits both oncogenic and tumor suppressive properties [32,33] and regulates multiple aspects
of pancreatic tumor development and progression [34,35]). Another miR, miR-3653, is particularly
interesting due to its abundance in both BON and QGP cells and its negative association with tumor
size, lymph node metastasis, and poor survival in glioma [36], its metastasis and EMT suppressor
function in colon cancer cells [37], and its upregulation in panNET patients with distant metastases [38].
Taken together, it appears that miRs involved in mature β-cell function are preferentially expressed
in NT-3 cells and lower or absent in BON and QGP. This; however, does not apply for members of
the miR-17–92 cluster, which are likely to exert tumor-associated functions in BON and QGP cells.
For a list of the more abundantly expressed miRs and their functional activities see Table S2.
2.6. Migratory Activity of BON and QGP Cells
The neuroendocrine and well-differentiated epithelial phenotype of BON and QGP cells described
above is suggestive of a low invasive potential. To test this prediction more directly we measured
random and directed migratory activity in a chemokinesis and a chemotaxis setup, respectively, in
real-time on an xCELLigence platform. In the chemotaxis setup, cells are attracted by the high-serum
content in the lower chamber and, if motile, move through the membrane pores towards the lower
chamber. We observed that under chemokinesis conditions BON cells exhibited a rapid and transient
but comparatively weak migratory response (Figure 5A, QGP cells were not tested). However, when
the assay is run with a chemotaxis setup with 10% fetal bovine serum (FBS) as attractant, neither BON
nor QGP cells showed any detectable migratory activity (regardless of whether collagen I or collagen
IV was used for coating), in contrast to highly invasive Panc1 cells which were used as a positive
control [39] (Figure 5B). It remains to be seen; however, if certain cytokines or growth factors can
stimulate migration or invasion in BON and QGP cells.Cancers 2020, 12, x FOR PEER REVIEW 9 of 18 
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3. Discussion
The goal of the present study was to confirm the authenticity of the BON and QGP cell lines
and to better characterize their state of epithelial and pancreatic endocrine differentiation. To assess
the neuroendocrine phenotype of our BON and QGP1 cultures, we analyzed expression of a panel
of classical neuroendocrine markers in comparison to a lymph node-derived cell line (NT-3) from
a male patient with well-differentiated panNET. In both BON and QGP, SYP and, to a lesser extent,
CgA protein was readily detectable by immunoblotting but was clearly lower than in NT-3 cells. This is
in line with results from an immunohistochemical study reporting CgA protein to be weak in BON
and absent in QGP cells [5]. CgA has been shown to be a reliable serum diagnostic biomarker for
panNETs but not for insulinomas [40]. Both BON and QGP cells were positive for SSTR2 and -5 mRNA,
although levels were 10–20-fold lower compared to NT-3. Exner and coworkers assessed SSTR mRNA
expression in BON and QGP1 cells in comparison to panNET and siNET tissues, and observed that
while the abundance of SSTR2 mRNA in BON and QGP cells was approximately 100-fold lower, that of
SSTR5 mRNA in BON cells was close to that in NET tissues [8]. From these findings and additional
expression data of other neuroendocrine markers (NCAM1, NF68, MAP2) we conclude, in agreement
with others [5], that both BON and QGP cells possess a neuroendocrine phenotype.
Regarding the expression of EMT markers in BON and QGP we detected, by immunoblotting,
strong expression of E-cadherin in BON, QGP, and NT-3 cells. Readily-detectable levels of E-cadherin
in BON cells have also been reported by Wu and colleagues [41]. The epithelial differentiation of these
cell lines was confirmed by low protein expression of the mesenchymal marker Vimentin as compared
to the poorly differentiated and VIMhigh PDAC cell lines, Panc1 and MiaPaCa2 [42]. The epithelial
phenotype may, in addition, be maintained by high expression of miR-3653 [38], which has been
shown to inhibit mesenchymal transition by targeting the EMT-associated TF Zeb2. In this context, it is
noteworthy that members of the miR-200 family, whose members are strong inducers of epithelial
differentiation and are repressed by Zeb1 [43], were not among the miRs identified in BON, QGP,
and NT-3 cells.
Our qPCR-based expression analysis revealed that mRNA levels of INS were much lower in BON
and QGP than in NT-3 cells. The high abundance of INS mRNA in NT-3 cells is in line with detection of
the protein in NT-3 culture supernatants [9]. Transcript levels of other genes implicated in regulation
of insulin synthesis and secretion were also lower in BON/QGP (i.e., PDX1, ISL1, MAFA, and ACVR1C).
The comparatively low expression in BON and QGP of ALK7, a receptor from the TGF-β/activin receptor
superfamily that suppresses ectopic proliferation during panNET development [15], may contribute
to the higher Ki67 index observed in both cell lines compared to panNET tissues and primary cell
cultures [9]. Finally, mRNA levels of NKX2.2, a TF important for maintenance of β-cell identity,
and NKX6.1, a related TF important for islet endocrine cell development and insulin secretion in β-cells,
were lower in BON and QGP compared to NT-3 cells. Regarding markers for other hormone-producing
cell types, we found GCG mRNA levels in BON and QGP cells to be two orders of magnitudes lower
than in NT-3 cells. Of note, expression of PAX6, which can activate transcription of GCG, is also
lower in BON and QGP relative to NT-3 cells. SST mRNA was dramatically increased in QGP over
that in NT-3 and BON cells, which is in agreement with the establishment of the QGP cell line from
a SST-producing islet cell carcinoma [3].
Remarkably, some marker genes of immature, non-functional β-cells (i.e., NEUROD1), and of
pancreatic and pancreatic-endocrine progenitors not expressed during the final stage of β-cell
differentiation (i.e., NEUROG3), stand out in that their mRNA levels were more abundant in QGP
and BON than in NT-3 cells. It should be noted that NEUROG3 activates NEUROD1, which could
help to explain the comparatively high expression of NEUROD1 in BON and QGP cells. Yet other
TFs-encoding genes expressed in foregut endoderm and during early pancreatic budding (GATA4,
GATA6, FOXA2, PTF1A) were either expressed at equal levels among BON, QGP, and NT-3 cells
(differences <2-fold), or were 3–4-fold (GATA6, FOXA2) or even up to 70-fold (PTF1A) more abundant in
BON and QGP compared to NT-3 cells. The high PTF1A mRNA levels may be the result of absent (BON)
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or low (QGP) levels of miR-18a, which regulates expression of Ptf1a in pancreatic progenitors. Together,
the results from gene expression analyses of islet cell hormones and mature β-cell differentiation
markers provide evidence for the hypothesis that BON and QGP cells resemble immature β-cells or
pancreatic precursors, rather than mature functional β-cells. In contrast, in all panNETs analyzed by
Cejas and coworkers the mature cell transcriptional signature was stronger than that of progenitors [17].
The NGS-based identification of miRs expressed in BON and QGP cells yielded a large number of
miRs with potential involvement in panNET biology (see Table S1). The absent or only low expression
in BON or QGP compared to NT-3 cells of miR-15a/b, miR-375, and miR-182, which control β-cell
identity, β-cell mass, and upregulate INS expression and secretion [27,29,31], attests to the immature
β-cell/progenitor phenotype of BON and non-β-cell identity of QGP cells, respectively. This is further
strengthened by the absence in BON or QGP cells of yet other miRs, for which a role in endocrine
differentiation or β-cell function has been reported (23a, 27b-3p, 29c, 34a, 96, 103, 107, 124, 125b-5p,
130a/b, 152, 184, 192–5p, 195, 212/132, 335, 342, 376b-3p, 451) [18,44–46]. In summary, BON and QGP
cells express only few miRs specific to insulinomas or mature/functional β-cells and, if present,
transcript levels are low, which is consistent with the lack of INS expression in both lines. High levels of
miR-196a, miR-21, and miR-221 have been reported to be associated with tumor proliferation, advanced
stage, metastases, recurrence, or reduced survival [11,47] and mucinous precursor lesions of PDAC [48].
Moreover, miR-664b identified in both BON and QGP cells regulates multiple aspects of pancreatic
tumor development and progression and directly targets PAX6, which might help to explain the low
expression of PAX6 in BON and QGP cells (see Figure 4A). Like panNET, QGP cells exhibit coordinate
expression of miRs 17, 20, and 92, which are oncogenic in association with MYC [49]. Generally, some
of the tumor-associated miRs might contribute to the higher proliferation index of BON and QGP
compared to panNETs or authentic NET cell lines like miR-18a. This miR counteracts EGFR and AKT
to inhibit the proliferation of pancreatic progenitors [50] and might explain the poor sensitivity of
these cells to the mTOR inhibitor RAD001 (everolimus) [51]. This is of note given that everolimus is
being used for the treatment of patients with panNETs [51,52]. Interestingly, inhibition of mTOR by
everolimus has been shown to result in activation of Src in panNET cells [53]. Since Src is crucial for
their invasive and metastatic activities [54], the use of rapalogues could increase the migratory capacity
of BON and QGP cells on different scaffolds but in a therapeutic setting bears a potential risk of serious
side effects.
Our NGS-based analysis of miRs also allowed for the identification of previously unknown miRs.
The novel miRs identified here (15 in BON and 12 in QGP), some of them with extremely high RES
(up to 12,533), might be useful in further refining the subtype classification of BON and QGP cells
following elucidation of their biological function.
Based on the mRNA expression patterns and the identified miRs, we attempted to allocate BON
and QGP cells to one of the three transcriptional subtypes described by Sadanandam and colleagues [12].
Both BON and QGP cells can tentatively be associated with the MLP subtype, while NT-3 cells resemble
the IT subtype (Figure 6). This conclusion is based on the finding that BON and QGP have generally
lower expression of markers of a neuroendocrine phenotype (SYP, CgA), but higher expression of
pancreatic/islet cell precursor genes that are not expressed during the final stage of β-cell differentiation
(i.e., NEUROG3). Conversely, NT-3 cells have generally much lower, although readily detectable,
mRNA levels of pancreatic precursor genes. Most importantly, BON and QGP fail to express significant
mRNA levels of genes typical of mature/functional β-cell differentiation (INS1, MAFA, ISL1, PDX1,
ACVR1C) or in maintaining mature β-cell function and identity (MAFA, PDX1, NKX2.2, NKX6.1).
All these genes are poorly expressed in MLP tumors, but high in IT tumors [12] and in NT-3 cells [9].
In the above mentioned study, a 30-miR human panNET signature was clustered into three distinct
subsets (miR-cluster-1, -2, and -3), and each of these three miR-clusters was enriched in one of the three
mRNA transcriptome subtypes [12]. When we compared this 30-miR signature with the miRs identified
in BON and QGP cells, we found six miRs that were shared by QGP (7–1, 17, 20a, 92a, 221) and BON
(17, 20a, 126, 221) cells. However, except for miRs 17 and 20a, the abundance was too low to be
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of biological significance. Taken together, the data from both the developmental mRNA survey
and the overall miR expression pattern suggest that BON and QGP cells are unlikely to belong to the IT
transcriptomic subtype but, rather, resemble the MLP subtype (Figure 6).
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Figure 6. Cartoon showing allocation of NT-3, BON, and QGP cells to the transcriptional subtypes
of pancreatic NET (panNET) described in [12]. Based on the data from phenotypic characterization
and gene expression analyses, NT-3 cells can be classified as IT, while BON and QGP cells more closely
resemble the MLP subtype. Due to the well-differentiated epithelial phenotype, the expression of
miRs with anti-EMT and anti-metastatic function, and the low or absent migratory activity in vitro,
BON and QGP cells have been tentatively grouped into the MLP-1 sub-subtype of tumors. In case
of EMT marker (i.e., VIM), expression in the MLP-1 sub-subtype can be shown to be as high as in
the MLP subtype (combining MLP-1 and MLP-2), then BON and QGP cells more likely belong to
a still hypothetical subtype that combines features of both MLP and IT tumors (designated IT/MLP-1
Intermediate, yellow boxes with stippled lines). Tumors of this class are assumed to be still functional
with respect to serotonin secretion of BON and SST secretion of QGP cells. Adapted from [12], modified.
Within the MLP subtype of panNETs one half of primary tumor samples was poorly metastatic
(termed MLP-1) while the other half (termed MLP-2) had high metastatic potential [12]. Our results on
the low-to-absent migratory activity of BON and QGP cells in vitro is in line with high expression of
the invasion suppressor E-cadherin in BON [41,55] and QGP cells, and low or undetectable expression
of Vimentin, together predicting a low invasive/metastatic capacity. In orthotopic mouse models,
wild-type BON cells showed a variable and comparatively low metastatic spread to the liver with
metastases found in 0% [56], 12.5% [41], or ~50% [57] of transplanted mice, while equivalent data
are not available for QGP1. This is also supported by the miR data in three ways. i) Expression
in BON and QGP of miRs that inhibit migration, invasion, metastasis, and EMT [35,37,38,58,59];
ii) the identification in QGP but not BON cells of only two, weakly expressed miRs associated with
metastases of panNET, miR-21 (RES = 9) and miR-let7b (RES = 6); and iii) the absence in the BON
and QGP lines of mouse MLP and metastasis-specific miRs highly expressed in the majority of
the samples in miR-cluster-1 and -2 from human panNET [12,60], and of miRs previously shown by us
to be associated with NET metastases [11]. Together with the observation that BON and QGP cells
display only low migratory in vitro and low-to-moderate metastatic activity in vivo, both lines are;
therefore, likely to belong to the MLP-1 sub-subtype, where 5% of the tumors were associated with
distant metastases vs. 45% of the MLP-2 subtype [12] (Figure 6). However, Sadanandam and coworkers
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identified high VIM expression in MLPs compared with ITs, although no data were presented as
to whether this applies to both MLP-1 and MLP-2 tumors. Since BON and QGP cells are unlikely
to have undergone an EMT—both lines are CDH1high/VIMlow and abundantly express miR-3653,
which suppresses metastasis and EMT [37,38]—they might represent yet another (still hypothetical)
subtype that combines features of both MLP and IT (designated “IT/MLP-1 Intermediate” in Figure 6).
Intriguingly, Sadanandam et al. found six human MLP tumors that clustered more closely than most
MLPs with human and mouse ITs, and these were suspected to represent a subset of human MLPs with
increased IT-specific genes [12]. In addition, they described another three human panNETs that were
positive for both insulin and ENPP2 (designated Ins-hi MLP subtype) and thus combined features of
MLP tumors (ENPP2high and INSlow) and IT tumors (ENPP2low and INShigh). This led these authors
to suggest that ENPP2 along with insulin may serve as a biomarker that can be used to distinguish
not only the IT and MLP subtypes, but also sub-subtypes of MLPs [12]. It will be interesting to see if
the subtype classification of the BON and QGP cell lines can be further refined with the use of ENPP2,
and insulin/serotonin [1,61] or SST [3], respectively.
The expression of EMT genes in MLPs suggested that a dedifferentiation process has occurred in
a subset of tumors that progressed from IT into metastatic MLP tumors [12], revealing the existence of
an early and separate cell or pathway of origin for prometastatic MLP-2 tumors. In contrast, MLP
tumors with an epithelial phenotype (VIMlow, CDH1high) and Ins-hi, or by analogy SST-hi, arise either
directly from mature pancreatic β- or δ-cells or via progression of β- or δ-cell–derived IT tumors.
Such a scenario may hold true for QGP cells given the high SST expression and the relatively high
co-expression of PAX4 and PAX6.
As a word of caution it should be mentioned that the BON and QGP lines harbor mutations in
tumor suppressor and oncogenes that do not normally occur in panNETs, and may have been acquired
at some point during in vitro culture as a result of selective pressure (i.e., TSP53 [5,7], CDKN2A/B,
and DPC4 [5,62]). Given the potential impact of these cancer-associated mutations on various aspects
of cellular and neuroendocrine function, one should be aware that data derived from therapeutic
interventions in these cell lines may not be predictive of the clinical response in panNET patients.
4. Conclusions
In this study, we showed that the BON and QGP cell lines display a neuroendocrine
and well-differentiated phenotype, but, in contrast to the NT-3 line, do not exhibit a gene signature
characteristic of mature/functional pancreatic islet/β-cells. Rather, they preferentially express genes
normally activated during pancreatic development or in early endocrine progenitors, compatible with
arrested differentiation. The absence of mesenchymal traits, the expression of microRNAs involved in
suppression of invasion and metastasis, as well as the low migratory and metastatic activity further
suggest that BON-1 and QGP-1 cells have arisen either from mature islet cells or via progression of β-
or δ-cell–derived tumors of the IT transcriptional subtype, rather than by dedifferentiation of IT tumors
into tumors with a MLP-2 transcriptional subtype. We conclude that both cell lines are principally
relevant as neuroendocrine tumor models and that the results of this study could aid in deciding
whether or not the use of these cell lines is feasible for novel study objectives.
5. Material and Methods
5.1. Cells
The BON cell line was established from a functional human pancreatic carcinoid tumor of
the pancreas [1] and was provided by C.M. Townsend (University of Texas, Galveston, TX, USA). BON
cells are functional with respect to secretion of serotonin [1,61], a monoamine that is released from a subset
of pancreatic islet cells and β-cells along with insulin in a glucose-dependent manner [63]. The QGP-1
line was generated from a primary pancreatic carcinoma [2] and was purchased from the JCRB Cell Bank
(Osaka, Japan). Cells were cultured in DMEM/Ham’s F12 (1:1) (BON), or RPMI 1640 (QGP), supplemented
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with 10% FBS and penicillin/streptomycin. The NT-3 cell line was established and characterized by
us recently [9]. NT-3 cells were maintained under semi-adherent conditions in collagen IV-coated
culture flasks in RPMI 1640 medium supplemented with 10% FBS, penicillin/streptomycin, HEPES, EGF
(20 ng/mL), and FGF2 (10 ng/mL) (Peprotech, Hamburg, Germany).
Human WI-38 fibroblasts were included as negative control in the qPCR assays, while the pancreatic
ductal adenocarcinoma (PDAC) cell lines Capan2, Panc1, and MiaPaCa2 were used as controls for
expression of E-cadherin (encoded by CDH1) or Vimentin (encoded by VIM) [42]. Since Panc1 cells
are highly invasive, these cells were used along with another non-motile PDAC cell line, Colo357,
as controls in the migration assays. Panc1 cells are of ductal/exocrine origin; however, they possess
some neuroendocrine features, such as expression of CgA and SSTR2 [64] and the potential to be
transdifferentiated into insulin-producing cells [65–68].
5.2. RNA Isolation and Quantitative Real-Time RT-PCR (qPCR)
RNA isolation and purification for qPCR was done with PeqGold (PeqLab, Erlangen, Germany).
Total RNA (2.5 µg) was reverse transcribed to cDNA with 200 U M-MLV-Reverse Transcriptase
and 2.5 µM random hexamers. The cDNA samples (50 ng RNA equivalent in a 20 µL reaction
volume) were subjected to PCR in duplicate on an I-Cycler (BioRad, Munich, Germany) using
Maxima SYBR Green Mastermix (Thermo Fisher Scientific, Waltham, MA, USA). The threshold (Ct)
values of the genes-of-interest (GOI) were normalized to those of the housekeeping gene (HKG),
TATA box-binding protein (TBP), in the same reaction using the 2-∆∆Ct method, and are displayed as
relative mRNA expression. TBP was chosen for normalization since it is representative of an HKG
with moderate-to-low expression (Ct values of ~25), being in the range of the Ct values (between 20
and 30) for most of the GOIs analyzed here. For a list of PCR primers see Table S3.
5.3. Immunoblot Analysis
Cell lysis and immunoblotting was essentially performed as described previously [42]. In brief,
cells were washed once with ice-cold PBS and lysed with PhosphoSafe lysis buffer (Merck Millipore,
Darmstadt, Germany). Following clearance of the lysates by centrifugation, their total protein
concentrations were determined with the DC Protein Assay (BioRad). Equal amounts of proteins
were fractionated by PAGE on mini-PROTEAN TGX any-kD precast gels, or TGX Stain-Free FastCast
gels (BioRad) and blotted to PVDF membranes. Membranes were blocked with nonfat dry milk or
bovine serum albumin and incubated with primary antibodies (CgA: Monoclonal Mouse Anti-Human
Chromogranin A, clone DAK-A3, Dako, Glostrup, Denmark; SYP: Anti-Synaptophysin, Dako; SSTR2:
Anti-Somatostatin Receptor 2 antibody [UMB1]-C-terminal #ab134152, Abcam, Cambridge, UK)
overnight at 4 ◦C. After washing and incubation with horseradish peroxidase-linked secondary
antibodies, chemoluminescent detection of proteins was done on a ChemiDoc XRS imaging system
(BioRad) with Amersham ECL Prime Detection Reagent (GE Healthcare, Munich, Germany). The signals
for the proteins of interest were normalized to those for the housekeeping genes GAPDH or HSP90.
5.4. Next Generation Sequencing of MicroRNAs
The isolation and purification of total RNA for next-generation sequencing (NGS) was
done with Qiagen miRNeasy Mini Kit (Qiagen, Hilden, Germany). Total RNA was quality
controlled on a TapeStation 4200 (Agilent, Waldbronn, Germany). RIN Scores were above 7 for
all samples. A total of 200 ng of input total RNA were used to construct sequencing libraries using
the NEXTFLEX®Small RNA-Seq Kit v3 for Illumina®Platforms (PerkinElmer, Waltham, MA, USA)
following the manufacturers protocol for a gel-free workflow. Resulting libraries were quality
controlled on a TapeStation 4200 (Agilent) and showed a clean peak at approximately 160 base pairs
(bp). Quantification was performed on a Qubit 2.0 fluorometer (Thermo Fisher Scientific, location).
The two libraries (corresponding to BON and QGP cells) were multiplexed and sequenced on a HiSeq
4000 (Illumina, San Diego, CA, USA) lane with 50 bp single-read sequencing.
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Quality of raw fastq files was assessed using fastp v0.20.0 [69] (default options, percentage of
unqualified bases limited to 30% and minimum read length was set to 30 bp). Additionally, reads
were trimmed from 5’ end 3’ by 5 bp and adapter sequences (TGGAATTCTCGGGTGCCAAGG) were
trimmed off. Trimmed reads mapped to GRCh38 using STAR aligner v2.7.2b [70] and Gencode v24
annotations. Additionally, miRNA annotations from Gencode V29 were added (ENCODE reference
ENCSR564GPK). Resulting mapping files were filtered using R v3.6.1 (https://www.rdocumentation.
org/packages/base).
5.5. Migration Assays
We employed the xCELLigence®DP system (ACEA Biosciences, San Diego, CA, USA, distributed
by OLS, Bremen, Germany) to measure chemokinesis/-taxis of BON and QGP cells in real-time. Briefly,
CIM plates-16 were prepared according to the instruction manual and previous descriptions [39].
The underside of the upper chambers of the CIM plate-16 was coated with 30 µl of collagen I or collagen
IV to facilitate adherence of the cells and enhance signal intensities. After filling the wells of the lower
and upper chambers of the CIM plate-16 with medium (containing 1% FBS in both the lower and upper
chamber for the chemokinesis setup, or 10% FBS in the lower chamber and 0.5% FBS in the upper
chamber for the chemotaxis setup), the plates were assembled and equilibrated in the incubator for 1 h.
In both instances, 50,000–100,000 cells are applied to the upper chamber of each well. Data acquisition
was done at intervals of 15 min and analyzed with RTCA software, version 1.2 (ACEA Biosciences).
5.6. Statistical Analysis
Statistical significance was calculated using the Mann–Whitney U test or the Wilcoxon test. Results
were considered significant at p < 0.05 (indicated in the figures by asterisks).
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